KRAS mutations occur in >90% of #PancreaticCancer #patients & the G12D variant is most common. In a @AACR @CD_AACR #OpenAccess #researchpaper @sam_kemp20 & team use a G12D specific inhibitor in relevant models of #pancsm ➡️very promising💜 @OncoAlert 🚨 Tweet added by Ben Westphalen @BenWestphalen | Pikagi

Pikagi

@BenWestphalen

Ben Westphalen

2 years

KRAS mutations occur in >90% of #PancreaticCancer #patients & the G12D variant is most common. In a @AACR @CD_AACR #OpenAccess #researchpaper @sam_kemp20 & team use a G12D specific inhibitor in relevant models of #pancsm ➡️very promising💜 @OncoAlert 🚨

Tweet media one

2

24

63

Replies

@pashtoonkasi

Pashtoon Kasi MD, MS

2 years

@BenWestphalen @AACR @CD_AACR @sam_kemp20 @OncoAlert @DuctalvsAcinar @KReissMD @KenOliveLab @letswinpc @lustgartenfdn @PanCAN @PancPathologist @HCCvPDAC @DelgiornoKathy It’s been a while since we had the initial press release about the drug #MRTX1133 . Rumor has it that there have been some solubility issues? Maybe anyone else has updates? Pts waiting. In other news, #KRASG12D degrader trial enrolling #ASP3082 . @OncoAlert

1

0

9

@drcmassard

Christophe Massard

2 years

@BenWestphalen @AACR @CD_AACR @sam_kemp20 @OncoAlert @DuctalvsAcinar @KReissMD @pashtoonkasi @KenOliveLab @letswinpc @lustgartenfdn @PanCAN @PancPathologist @HCCvPDAC @DelgiornoKathy Important notion and all the non-KRAS PCAD! Major message for all physicians

0

0

3